EGFR and adrenal cortex carcinoma: Guidelines suggest that patients without sensitizing EGFR mutations not be treated with EGFR TKIs in any line of therapy.6 Most patients with sensitizing EGFR mutations are nonsmokers or former light smokers with ACC.7 Therefore, EGFR TKIs perform well in ACC patients, but few provide clinical benefits for SCC patients.